Clinical & Experimental Metastasis

, Volume 19, Issue 4, pp 351–358 | Cite as

FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: An immunohistochemical and image analysis study

  • Hussam H. Mady
  • Mona F. MelhemEmail author


The FHIT gene, a member of the histidine triad family has been identified as a tumor suppressor gene. Molecular genetic approaches to determine alterations in the FHIT gene in colorectal cancers have produced varying results with reported abnormalities of the FHIT gene transcripts in 13% to 50% of cases studied. FHIT has been reported to be involved in the regulation of apoptosis and cell cycle in cell culture systems. Immunohistochemical (IHC) studies of FHIT expression in human colon cancer and its correlation to apoptosis and clinical prognosis have been sparse. We studied 100 human colorectal cancers by IHC and a computerized image analysis (CIA) method to evaluate FHIT expression and the rate of apoptosis in tumors and corresponding mucosae. Follow-up data for at least five years was available for all patients. We correlated the results with tumor grade, stage and clinical prognosis. We used commercially available polyclonal anti FHIT antibody and Apoptaq kit on paraffin-embedded tumors and their corresponding mucosae and the SAMBA 4000 CIA system to evaluate the labeling index (LI), the mean optical density (MOD) of the stain and calculate a quick score (QS). The LI is the ratio of positively stained areas to the total area of the tissues examined, the MOD represents the concentration of the positive stain as measured per positive pixels and the QS a numeric product of the LI and MOD for each microscopic area examined. Image analysis of IHC staining of the tumor sections defined three main groups based on the reactivity of the anti FHIT polyclonal antibody. Group I included 23 cases where the LI was less than 55% with a mean of 36%. Eight cases in this group showed complete loss of FHIT expression. Group II included 41 cases where the LI was between 55% and 65% with a mean of 60%. Group III was composed of 36 cases where the LI was more than 65% with a mean of 69%. Our data showed that the absence or reduction of FHIT protein in the tumors, relative to morphologically normal mucosa, plays a role in the development of a few colorectal cancers (23%). Poorly differentiated carcinomas showed absent or decreased FHIT. A reduction of FHIT was positively correlated with the rate of distant metastases and worse prognosis. Over-expression of FHIT is directly proportional to the apoptotic rate in the tumors examined. CIA provides an objective and accurate assessment of the staining patterns and generates numerical data evaluating intensity better than depending on subjective light microscopy alone.

apoptosis colon adenocarcinoma FHIT image-analysis immunohistochemistry 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    De Vita Jr VT, Hellman S, Rosenberg SA. Cancer: Principle and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven 1997.Google Scholar
  2. 2.
    Ohata M, Inoue H, Cotticelli MG et al. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal cell carcinoma-associated t(3;8) breakpoint is abnormal in digestive tract cancers. Cell 1996; 84: 587–97.CrossRefGoogle Scholar
  3. 3.
    Sozzi G, Veronese ML, Negrini M et al. The FHIT gene at 3p14.2 is abnormal in lung cancer.Cell 1996; 85: 17–26.PubMedCrossRefGoogle Scholar
  4. 4.
    Virgilio L, Shuster M, Gollin SM et al. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996; 93: 9770–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Negrini M, Monaco C, Vorechovsky I et al. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56: 3173–9.PubMedGoogle Scholar
  6. 6.
    Greenspan DL, Connolly DC, Wu R et al. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.Cancer Res 1997; 57: 4692–8.PubMedGoogle Scholar
  7. 7.
    Simon B, Bartsch D, Barth P et al. Frequent abnormalities of the putative tumor suppressor gene FHIT at 3p14.2 in pancreatic carcinoma cell lines. Cancer Res 1998; 58: 1583–7.PubMedGoogle Scholar
  8. 8.
    Chen YJ, Chen PH, Lee MD et al. Aberrant FHIT Transcripts in cancerous and corresponding non-cancerous lesions of the digestive tract. Int J Cancer 1997; 72: 955–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Hibi K, Taguchi M, Nakamura H et al. Alternative splicing of the FHIT gene in colorectal cancers. Jpn J Cancer Res 1997; 88: 385–8.PubMedGoogle Scholar
  10. 10.
    Saitoh Y, Waxman I, West AB et al. Prevalence and digestive biologic features of flat colorectal adenomas in a north American population. Gastroenterology 2001; 120: 1657–65.PubMedCrossRefGoogle Scholar
  11. 11.
    Hao XP, Willis JE, Pretlow TG et al. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 2000; 60: 18–21.PubMedGoogle Scholar
  12. 12.
    Mori M, Mimori K, Masuda T et al. Absence of Msh2 protein expression is associated with alteration in the FHIT locus and FHIt protein expression in colorectal carcinoma. Cancer Res 2001; 61:7379–82.PubMedGoogle Scholar
  13. 13.
    Kerr JFR, Wyllie AH, Currie AR. Apoptosis basic biologic phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239–57.PubMedGoogle Scholar
  14. 14.
    William GT, Smith CA. Molecular regulation of apoptosis. Genetic controls on cell death. Cell 1993; 74: 777–79.CrossRefGoogle Scholar
  15. 15.
    Sinicrope FA, Roddey G, McDonnell TJ et al. Increased Apoptosis accompanies neoplastic development in the human colorectum. Clinical Cancer Res 1996; 2: 1999–2006.Google Scholar
  16. 16.
    Badi A, Pasricha PJ, Akhtar AJ. Inhibition of Apoptosis during development of colorectal cancer. Cancer Res 1995; 55: 1811–6.Google Scholar
  17. 17.
    Haake AR, Polakowska RR. Cell death by apoptosis in epidermal biology. J Invest Dermatol 1993; 101: 107–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124: 1–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Sinicrope FA, Ruan S, Cleary KR et al. Bcl-2 and P53 oncoprotein expression during colorectal tumorgenesis. Cancer Res 1995; 55: 237–41.PubMedGoogle Scholar
  20. 20.
    Hague A, Moorghren M, Hicks D et al. bcl-2 expression in human colorectacl adenomas and carcinomas. Oncogene 1994;9: 3367–70.PubMedGoogle Scholar
  21. 21.
    Sard L, Accornero P, Tornielli S et al. The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle control. Proc Natl Acad Sci USA 1999; 96(15): 8489–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Ji L, Fang B, Yen N et al. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999; 59(14): 3333–9.PubMedGoogle Scholar
  23. 23.
    Croce CM, Sozzi G, Huebner K et al. Role of FHIT in human cancer. J Clin Oncol 1999; 17: 1618–24.PubMedGoogle Scholar
  24. 24.
    Bruke L, Khan MA, Freedman AN et al. Allelic deletion analysis of the FHITgene predicts poor survival in non-small cell lung cancer. Cancer Res 1998; 58: 2533–6.Google Scholar
  25. 25.
    Campiglio M, Pekarsky Y, Menard S et al. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999; 59: 3866–9.PubMedGoogle Scholar
  26. 26.
    Tomizawa Y, Nakajima T, Kohno T et al. Clinicopathological significance of FHIT protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998; 58: 478–83.Google Scholar

Copyright information

© Kluwer Academic Publishers 2002

Authors and Affiliations

  1. 1.Departments of PathologyUniversity of Pittsburgh and the Veterans' Administration Healthcare SystemPittsburghUSA

Personalised recommendations